As a potential treatment of COVID-19: Montelukast

Med Hypotheses. 2020 Sep:142:109828. doi: 10.1016/j.mehy.2020.109828. Epub 2020 May 11.

Abstract

It has been hypothesized that Montelukast, a cysteinyl leukotriene (cysLT) receptor antagonist, with effects of anti-inflammatory, suppress oxidative stress and reduce affect cytokine production, may limited progression of the disease on COVID-19 infection.

Publication types

  • Letter

MeSH terms

  • Acetates / therapeutic use*
  • Anti-Inflammatory Agents / therapeutic use
  • Betacoronavirus
  • COVID-19
  • COVID-19 Drug Treatment
  • Coronavirus Infections / drug therapy*
  • Cyclopropanes
  • Cytokines / metabolism
  • Disease Progression
  • Humans
  • Inflammation
  • Oxidative Stress
  • Pandemics
  • Pneumonia, Viral / drug therapy*
  • Quinolines / therapeutic use*
  • Receptors, Leukotriene / metabolism
  • SARS-CoV-2
  • Sulfides

Substances

  • Acetates
  • Anti-Inflammatory Agents
  • Cyclopropanes
  • Cytokines
  • Quinolines
  • Receptors, Leukotriene
  • Sulfides
  • leukotriene D4 receptor
  • montelukast